discount tramadol online
Pharnext is focusing on severe neurodegenerative discount tramadol online in general and peripheral neuropathies in particular conditions which affect hundreds of millions of people worldwide. The initial target pathologies include Charcot Marie Tooth disease, an incapacitating orphan disease which affects 30,000 people in France, followed by related but more common discount tramadol online such as diabetic and toxic peripheral neuropathies. Pharnext will then rapidly broaden out its strategy to include other handicapping or life threatening conditions, such as Alzheimer's disease. Pharnext's vision is based on "drug repositioning" (the reuse of drugs that have already received market authorization), an increasingly attractive strategy for the pharmaceutical majors, with expenditure estimated at €5 billion per year. In fact, the pharmaceutical industry is suffering from a serious "innovation crisis"; the annual number of newly approved prescription drugs has steadily decreased over the last 15 years and, furthermore, many of these compounds are only marginally effective and indeed often poorly tolerated. Pharnext's "drug multi positioning" approach consists in extend the indications of existing drugs to other target pathologies. Orphan discount tramadol online generally represent the simplest models of complex conditions and so this is why the company is initially concentrating on a number of orphan discount tramadol online while simultaneously screening in models of more common pathologies in the same therapeutic area. At present, Pharnext has already identified over 50 generic drugs used to treat other discount tramadol online and which are likely to improve the condition of patients suffering from Charcot Marie Tooth disease and other peripheral or central neuropathies. These molecules have been tested in vitro and in vivo since the start of Q4 2007. The first patent applications covering the results of this initial phase were filed in November 2007. Pharnext was founded by a longstanding, internationally renowned team, including Professor Daniel Cohen, Drs Ilya Chumakov, Oxana Guerassimenko & Serguei Nabirotchkine and Loïc Heidsieck. The company has been awarded Young Innovative Company fiscal status and currently employs 8 staff. Its offices are located in Paris, within the "Pépinière Santé Cochin" business incubator. For more information, visit our web site: www.pharnext.com. ... discount tramadol online